These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 33489472)

  • 1. Single-cell transcriptome analysis of CAR T-cell products reveals subpopulations, stimulation, and exhaustion signatures.
    Wang X; Peticone C; Kotsopoulou E; Göttgens B; Calero-Nieto FJ
    Oncoimmunology; 2021 Jan; 10(1):1866287. PubMed ID: 33489472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single-cell multiomics dissection of basal and antigen-specific activation states of CD19-targeted CAR T cells.
    Bai Z; Lundh S; Kim D; Woodhouse S; Barrett DM; Myers RM; Grupp SA; Maus MV; June CH; Camara PG; Melenhorst JJ; Fan R
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34006631
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Suematsu M; Yagyu S; Nagao N; Kubota S; Shimizu Y; Tanaka M; Nakazawa Y; Imamura T
    Front Immunol; 2022; 13():770132. PubMed ID: 35154098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single-Cell Transcriptomic Analysis Reveals BCMA CAR-T Cell Dynamics in a Patient with Refractory Primary Plasma Cell Leukemia.
    Li X; Guo X; Zhu Y; Wei G; Zhang Y; Li X; Xu H; Cui J; Wu W; He J; Ritchie ME; Weiskittel TM; Li H; Yu H; Ding L; Shao M; Luo Q; Xu X; Teng X; Chang AH; Zhang J; Huang H; Hu Y
    Mol Ther; 2021 Feb; 29(2):645-657. PubMed ID: 33278564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revealing the impact of CD70 expression on the manufacture and functions of CAR-70 T-cells based on single-cell transcriptomics.
    Cheng J; Zhao Y; Hu H; Tang L; Zeng Y; Deng X; Ding S; Guo AY; Li Q; Zhu X
    Cancer Immunol Immunother; 2023 Oct; 72(10):3163-3174. PubMed ID: 37382633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxicity and exhaustion markers of chimeric antigen receptor T cells targeting BCMA in multiple myeloma cell lines between patients and healthy donors.
    Prasongtanakij S; Preedagasamzin S; Jittorntrum B; Anurathapan U; Puavilai T; Niparuck P; Chantrathammachart P; Piyajaroenkij T; Uaesoontrachoon K; Uchibori R; Ozawa K; Ohmine K; Hongeng S
    Eur J Haematol; 2024 Feb; 112(2):248-256. PubMed ID: 37222081
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving CAR-T immunotherapy: Overcoming the challenges of T cell exhaustion.
    Gumber D; Wang LD
    EBioMedicine; 2022 Mar; 77():103941. PubMed ID: 35301179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Manufacturing chimeric antigen receptor T cells from cryopreserved peripheral blood cells: time for a collect-and-freeze model?
    Palen K; Zurko J; Johnson BD; Hari P; Shah NN
    Cytotherapy; 2021 Nov; 23(11):985-990. PubMed ID: 34538575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tonic-signaling chimeric antigen receptors drive human regulatory T cell exhaustion.
    Lamarche C; Ward-Hartstonge K; Mi T; Lin DTS; Huang Q; Brown A; Edwards K; Novakovsky GE; Qi CN; Kobor MS; Zebley CC; Weber EW; Mackall CL; Levings MK
    Proc Natl Acad Sci U S A; 2023 Apr; 120(14):e2219086120. PubMed ID: 36972454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular and Functional Signatures Associated with CAR T Cell Exhaustion and Impaired Clinical Response in Patients with B Cell Malignancies.
    Beider K; Itzhaki O; Schachter J; Grushchenko-Polaq AH; Voevoda-Dimenshtein V; Rosenberg E; Ostrovsky O; Devillers O; Shapira Frommer R; Zeltzer LA; Toren A; Jacoby E; Shimoni A; Avigdor A; Nagler A; Besser MJ
    Cells; 2022 Mar; 11(7):. PubMed ID: 35406703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors.
    Chang ZL; Silver PA; Chen YY
    J Transl Med; 2015 May; 13():161. PubMed ID: 25990251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-Cell Analysis of Target Antigens of CAR-T Reveals a Potential Landscape of "On-Target, Off-Tumor Toxicity".
    Zhang Y; Li Y; Cao W; Wang F; Xie X; Li Y; Wang X; Guo R; Jiang Z; Guo R
    Front Immunol; 2021; 12():799206. PubMed ID: 34975912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Distinct Transcriptional Program in Human CAR T Cells Bearing the 4-1BB Signaling Domain Revealed by scRNA-Seq.
    Boroughs AC; Larson RC; Marjanovic ND; Gosik K; Castano AP; Porter CBM; Lorrey SJ; Ashenberg O; Jerby L; Hofree M; Smith-Rosario G; Morris R; Gould J; Riley LS; Berger TR; Riesenfeld SJ; Rozenblatt-Rosen O; Choi BD; Regev A; Maus MV
    Mol Ther; 2020 Dec; 28(12):2577-2592. PubMed ID: 32755564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Leveraging Single-Cell Sequencing for Chimeric Antigen Receptor T Cell Therapies.
    Castellanos-Rueda R; Di Roberto RB; Schlatter FS; Reddy ST
    Trends Biotechnol; 2021 Dec; 39(12):1308-1320. PubMed ID: 33832782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Engineering memory-rich CAR-T cells by a piggyBac transposon system].
    Yagyu S
    Rinsho Ketsueki; 2023; 64(5):418-426. PubMed ID: 37271534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors.
    Lontos K; Wang Y; Joshi SK; Frisch AT; Watson MJ; Kumar A; Menk AV; Wang Y; Cumberland R; Lohmueller J; Carrizosa E; Boyerinas B; Delgoffe GM
    J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36914208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression.
    Mueller KP; Piscopo NJ; Forsberg MH; Saraspe LA; Das A; Russell B; Smerchansky M; Cappabianca D; Shi L; Shankar K; Sarko L; Khajanchi N; La Vonne Denne N; Ramamurthy A; Ali A; Lazzarotto CR; Tsai SQ; Capitini CM; Saha K
    J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36382633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Better by design: What to expect from novel CAR-engineered cell therapies?
    Luginbuehl V; Abraham E; Kovar K; Flaaten R; Müller AMS
    Biotechnol Adv; 2022 Sep; 58():107917. PubMed ID: 35149146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing lisocabtagene maraleucel chimeric antigen receptor T-cell manufacturing for improved process, product quality and consistency across CD19
    Teoh J; Brown LF
    Cytotherapy; 2022 Sep; 24(9):962-973. PubMed ID: 35610089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.